NO995901L - Vektor - Google Patents

Vektor

Info

Publication number
NO995901L
NO995901L NO995901A NO995901A NO995901L NO 995901 L NO995901 L NO 995901L NO 995901 A NO995901 A NO 995901A NO 995901 A NO995901 A NO 995901A NO 995901 L NO995901 L NO 995901L
Authority
NO
Norway
Prior art keywords
vector
noi
poi
tumour
interest
Prior art date
Application number
NO995901A
Other languages
English (en)
Other versions
NO995901D0 (no
Inventor
Susan Mary Kingsman
Christopher Robert Bebbington
Fiona Margaret Ellard
Miles William Carroll
Kevin Alan Myers
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO995901(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9711579.4A external-priority patent/GB9711579D0/en
Priority claimed from GBGB9713150.2A external-priority patent/GB9713150D0/en
Priority claimed from GBGB9714230.1A external-priority patent/GB9714230D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Publication of NO995901D0 publication Critical patent/NO995901D0/no
Publication of NO995901L publication Critical patent/NO995901L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Abstract

Vektor omfattende en nukleotidsekvens av interesse ("NOI") som koder for et produkt av interesse ("POI"). NOI og/eller POI er istand til å gjenkjenne en tumor slik at vektoren ved bruk er istand til å avlevere NOI og/eller POI til tumoren.
NO995901A 1997-06-04 1999-12-02 Vektor NO995901L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9711579.4A GB9711579D0 (en) 1997-06-04 1997-06-04 Therapeutic genes
GBGB9713150.2A GB9713150D0 (en) 1997-06-20 1997-06-20 Fusion proteins
GBGB9714230.1A GB9714230D0 (en) 1997-07-04 1997-07-04 Therapeutic genes
PCT/GB1998/001627 WO1998055607A2 (en) 1997-06-04 1998-06-04 Tumor targeted vector

Publications (2)

Publication Number Publication Date
NO995901D0 NO995901D0 (no) 1999-12-02
NO995901L true NO995901L (no) 2000-02-04

Family

ID=27268875

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995901A NO995901L (no) 1997-06-04 1999-12-02 Vektor

Country Status (16)

Country Link
US (6) US6852703B1 (no)
EP (2) EP1012259B1 (no)
JP (3) JP2002507117A (no)
CN (1) CN1224712C (no)
AT (1) ATE444358T1 (no)
AU (1) AU747602B2 (no)
CA (1) CA2292760A1 (no)
CY (1) CY1109686T1 (no)
DE (1) DE69841204D1 (no)
DK (1) DK1012259T3 (no)
ES (1) ES2332435T3 (no)
IL (1) IL132596A0 (no)
NO (1) NO995901L (no)
NZ (1) NZ500633A (no)
PT (1) PT1012259E (no)
WO (1) WO1998055607A2 (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US7276488B2 (en) * 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
IL132596A0 (en) * 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
EP2161286A1 (en) * 1999-11-18 2010-03-10 Oxford Biomedica (UK) Limited Antibodies
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
EP1412493B1 (en) 2001-08-02 2011-10-05 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
IL161229A0 (en) * 2001-10-02 2004-09-27 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications.
CA2463931A1 (en) * 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US7939059B2 (en) * 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
EP1504034B1 (en) * 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
CA2484930A1 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
KR20050048615A (ko) * 2002-08-19 2005-05-24 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
GB0300718D0 (en) 2003-01-13 2003-02-12 Ares Trading Sa Proteins
MXPA05012414A (es) 2003-05-21 2006-02-13 Ares Trading Sa Proteina secretada similar a tnf.
EP1621550A1 (en) * 2004-07-29 2006-02-01 Dompé S.P.A. Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
GT200500255A (es) * 2004-09-10 2006-04-10 Anticuerpos anti-5ta humanizados y conjugados anticuerpo anti-5ta/calicheamicina
WO2006044410A2 (en) * 2004-10-14 2006-04-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
US20070292390A1 (en) * 2004-10-29 2007-12-20 Dimitrov Dimiter S Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
NZ571208A (en) 2006-03-10 2011-12-22 Wyeth Corp Anti-5T4 antibodies and uses thereof
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP2064325B1 (en) 2006-09-01 2011-12-07 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
KR20090069330A (ko) * 2006-10-12 2009-06-30 와이어쓰 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
ES2535613T3 (es) * 2008-07-15 2015-05-13 Oxford Biomedica (Uk) Limited Método inmunoterapéutico
US20100166808A1 (en) * 2008-11-17 2010-07-01 Giovanni Marco Pauletti Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands
ES2683352T3 (es) 2009-04-13 2018-09-26 Inserm - Institut National De La Santé Et De La Recherche Médicale Partículas de HPV y usos de las mismas
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2597954T3 (es) * 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
NZ623810A (en) 2009-07-27 2015-10-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
KR101912335B1 (ko) 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
JP2014533929A (ja) 2011-09-23 2014-12-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー ５ｔ４およびｃｄ３に対する二重特異的結合性分子
US9265969B2 (en) * 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
IN2014DN07019A (no) 2012-01-24 2015-04-10 Pfizer
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
US20150224181A1 (en) 2012-09-14 2015-08-13 The United States Of America As Represented By The Secretary Department Of Health And Human Se Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
MX2016003660A (es) 2013-09-18 2016-12-20 Aura Biosciences Inc Conjugados de partícula similar a virus para el diagnóstico y tratamiento de tumores.
ES2904301T3 (es) 2014-11-03 2022-04-04 Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum Receptores de células T dirigidos contra Bob1 y usos de los mismos
EP4201955A1 (en) 2015-03-10 2023-06-28 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
AU2016302237B2 (en) 2015-08-03 2022-08-04 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
WO2017075537A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
WO2017075533A1 (en) * 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
EP3368656A4 (en) * 2015-10-30 2019-07-17 The United States of America, as represented by the secretary, Department of Health and Human Services TARGETED CANCER THERAPY
AU2018224094A1 (en) 2017-02-24 2019-09-19 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
CA3056542A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
CN108148905A (zh) * 2018-02-13 2018-06-12 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) 一段可作为抑郁症标记物的序列
CN111886024A (zh) 2018-03-08 2020-11-03 东莞凡恩世生物医药有限公司 抗tip-1抗体及其用途
EP3765493A2 (en) 2018-03-12 2021-01-20 Genmab A/S Antibodies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
EP0336562B1 (en) * 1988-03-04 1995-06-14 Cancer Research Campaign Technology Ltd. Improvements relating to antigens
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
CA2016897A1 (en) 1989-05-17 1990-11-17 John W. Wills Retrovirus-mediated secretion of recombinant products
WO1991000047A1 (en) 1989-06-30 1991-01-10 The Regents Of The University Of California Retrovirus detection
WO1992000092A1 (en) 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand for cd28 receptor on b cells and methods
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
EP0621338A3 (en) * 1993-04-21 1997-10-29 Ajinomoto Kk The interleukin-2 response blocking immunosuppressor.
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5439654A (en) 1994-03-10 1995-08-08 Steris Corporation Cutter for opening sterilant reagent cups
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
DK0706799T3 (da) 1994-09-16 2002-02-25 Merck Patent Gmbh Immunkonjugater II
WO1996009400A1 (en) 1994-09-19 1996-03-28 Systemix, Inc. Methods for genetically modifying hematopoietic stem cells
GB9423085D0 (en) 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
US5824762A (en) * 1994-11-28 1998-10-20 Dow Corning Toray Silicone Co., Ltd. Organopolysiloxane and method for the preparation of the same
AU5320296A (en) 1995-03-24 1996-10-16 Genetic Therapy, Inc. Modified viral envelope polypeptide
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
WO1997014809A2 (en) * 1995-10-16 1997-04-24 Dana-Farber Cancer Institute Novel expression vectors and methods of use
WO1997017090A1 (en) * 1995-11-07 1997-05-15 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
WO1997017457A2 (en) 1995-11-08 1997-05-15 Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US6348584B1 (en) * 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
IL132596A0 (en) 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector
DE19724502C1 (de) 1997-06-11 1998-10-08 Webasto Thermosysteme Gmbh Heizgerät
CA2338982C (en) * 1998-08-10 2011-03-15 Urogenesys, Inc. Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells
EP2161286A1 (en) * 1999-11-18 2010-03-10 Oxford Biomedica (UK) Limited Antibodies
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体

Also Published As

Publication number Publication date
NO995901D0 (no) 1999-12-02
NZ500633A (en) 2002-10-25
US20110065173A1 (en) 2011-03-17
US20060286634A1 (en) 2006-12-21
PT1012259E (pt) 2009-11-06
CN1258319A (zh) 2000-06-28
US7718627B2 (en) 2010-05-18
US20030018004A1 (en) 2003-01-23
DK1012259T3 (da) 2010-01-18
ATE444358T1 (de) 2009-10-15
JP2011000122A (ja) 2011-01-06
WO1998055607A2 (en) 1998-12-10
WO1998055607A3 (en) 1999-03-04
DE69841204D1 (de) 2009-11-12
US20090017532A1 (en) 2009-01-15
ES2332435T3 (es) 2010-02-04
CY1109686T1 (el) 2014-08-13
CA2292760A1 (en) 1998-12-10
EP1717248A1 (en) 2006-11-02
US8084249B2 (en) 2011-12-27
US20050032216A1 (en) 2005-02-10
JP2009153524A (ja) 2009-07-16
AU747602B2 (en) 2002-05-16
US6852703B1 (en) 2005-02-08
IL132596A0 (en) 2001-03-19
US7531648B2 (en) 2009-05-12
EP1012259B1 (en) 2009-09-30
AU7780198A (en) 1998-12-21
CN1224712C (zh) 2005-10-26
EP1012259A2 (en) 2000-06-28
JP2002507117A (ja) 2002-03-05

Similar Documents

Publication Publication Date Title
NO995901L (no) Vektor
DE69415163T2 (de) ZUZAMMENSETUNG ENTHALTEND 1,1,1,2,3,4,4,5,5,5,-DECAFLUORPENTAN UND n-PROPANOL
HU9501874D0 (en) Modified cutinases, dna, vector and host
NL194084B (nl) Roeten alsmede rubbersamenstellingen met dergelijke roeten.
DE69630300D1 (en) Operationshandschuhe aus neoprencopolymeren
NZ237198A (en) Zymogen form of protein c, dna, vector and use as a pharmaceutical
PL309388A1 (en) Modified cutinases, dna, vector and host
DE59410132D1 (de) Humanes zirkulierendes cytokin cc-1
EP0273800A3 (en) Hirudine variants, their use and preparation
FR2714074B1 (fr) Promoteurs des gènes GRA1, GRA2, GRA5 et GRA6 de toxoplasma gondii et vecteurs d'expression comprenant lesdits promoteurs.
DK1431391T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
DK0919621T3 (da) Human TAK1 og DNA der koder derfor
EP0287084A3 (en) Alcohols containing 2-methyl or 2-methoxyphenyl groups, and their use as flavouring agents
AU119245S (en) Decorator's hand tool
FR2677996B1 (fr) Vecteurs de clonage et/ou d'expression preparation et utilisation.
NO981707L (no) Xylanase, oligonukleotidsekvens som koder for xylanase og anvendelse derav
FI944281A0 (fi) Anomeeriset fluoriribosyyliamiinit
GB9710636D0 (en) Novel mixture
GB9604518D0 (en) Novel compounds
Gharavi Molecular cloning of the human lipoxygenase gene
Ito Studies on the processing of the exported proteins in Bacillus subtilis
Raghavachary Fracture generation on arbitrary surfaces using Voronoi polygons
Pepper The effects of goal specificity, goal difficulty and goal source on endurance performance
Hu The Molecular Basis of Carbonic Anhydrase II Defiency
Lin Molecular enzymology--characterization of two mitochondrial enzymes of DNA cloning techniques

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application